Alzheimer’s Risk Assessment Test from HealthLabs

The page documents ApoE E2/E3/E4 allele testing with ApoE4 carrier-status reporting. The exact performing laboratory and assay method are not identified on the product page - third-party sources map it to either a Quest or a Labcorp assay, but neither is confirmed for a given order.

The test is explicitly marketed as an Alzheimer's genetic-risk assessment built on the ApoE gene, described as one of the most well-researched genetic factors linked to Alzheimer's and dementia. The content matches the stated purpose directly.

Coverage is the ApoE gene - E2/E3/E4 alleles plus ApoE4 carrier status. It is a single-gene risk test with no amyloid, tau, GFAP, or NfL blood biomarkers.

The price of $149 is documented on the provider's category page and corroborated by an independent lab-test directory, with a 110% price guarantee advertised - but it is not visible on the product page itself. HSA or FSA eligibility is not stated.

The page explains the risk meaning of each allele - ApoE4 as higher risk, ApoE3 as neutral and most common, ApoE2 as lower risk - and frames results as input for health planning and provider discussions. No counseling or physician-review service is described.

Intent, analytes, and the 1 to 3 business day turnaround are clearly stated. Which underlying assay is performed, the laboratory identity, the assay method, and state restrictions are not stated on the product page and would need confirmation when ordering.

Ordering is online with genuine checkout, collection is a walk-in lab visit with no appointment required, and results land in the online account within one to three business days - the fastest and simplest access of the six panels.

The product page does not state how personal or genetic data is stored, retained, or shared. A site-wide privacy promise exists but is not product-specific, leaving the privacy picture for this test unconfirmed.